Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) EBIT: 2017-2025

Historic EBIT for Organogenesis Holdings (ORGO) over the last 9 years, with Sep 2025 value amounting to $20.7 million.

  • Organogenesis Holdings' EBIT rose 232.06% to $20.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year increase of 34.41%. This contributed to the annual value of -$1.3 million for FY2024, which is 110.24% down from last year.
  • Per Organogenesis Holdings' latest filing, its EBIT stood at $20.7 million for Q3 2025, which was up 264.81% from -$12.6 million recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' EBIT registered a high of $23.6 million during Q2 2021, and its lowest value of -$26.7 million during Q1 2025.
  • Its 3-year average for EBIT is -$668,455, with a median of -$1.3 million in 2023.
  • Per our database at Business Quant, Organogenesis Holdings' EBIT surged by 1,147.38% in 2021 and then tumbled by 3,025.78% in 2023.
  • Quarterly analysis of 5 years shows Organogenesis Holdings' EBIT stood at $19.8 million in 2021, then plummeted by 55.86% to $8.7 million in 2022, then plummeted by 114.56% to -$1.3 million in 2023, then surged by 905.28% to $10.2 million in 2024, then spiked by 232.06% to $20.7 million in 2025.
  • Its EBIT was $20.7 million in Q3 2025, compared to -$12.6 million in Q2 2025 and -$26.7 million in Q1 2025.